Therapy Detail

Therapy Name SF1126
Therapy Description

SF1126 is a prodrug of LY294002, a pan PI3K inhibitor with additional activity against BRD4, which potentially leads to decreased tumor growth (PMID: 23355037, PMID: 27496136).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SF1126 BRD4 Inhibitor 6 PI3K Inhibitor (Pan) 34 SF1126 is a prodrug of LY294002, a pan PI3K inhibitor with additional activity against BRD4, which potentially leads to decreased tumor growth (PMID: 23355037, PMID: 27496136).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
HRAS G12V malignant glioma sensitive SF1126 Preclinical - Cell line xenograft Actionable In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962). 25425962
PTEN loss prostate cancer sensitive SF1126 Preclinical - Cell line xenograft Actionable In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313). 18172313 24634413
PTEN inact mut glioblastoma multiforme sensitive SF1126 Preclinical - Cell line xenograft Actionable In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313). 18172313 24634413
Unknown unknown Advanced Solid Tumor not applicable SF1126 Phase I Actionable In a Phase I trial, SF1126 demonstrated safety and preliminary efficacy in patients with a variety of advanced solid tumors (PMID: 22921184). 22921184
Unknown unknown hepatocellular carcinoma not applicable SF1126 Preclinical - Cell line xenograft Actionable In a preclinical study, SF1126 inhibited proliferation of hepatocellular carcinoma cell lines in culture, and inhibited tumor growth in hepatocellular carcinoma cell line xenograft models (PMID: 27496136). 27496136
Clinical Trial Phase Therapies Title Recruitment Status
NCT02644122 Phase II SF1126 SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes Terminated
NCT03059147 Phase I SF1126 A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma Recruiting
NCT02337309 Phase I SF1126 SF1126 for Patients With Relapsed or Refractory Neuroblastoma Terminated